Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Hedgehog cell-signalling pathway inhibitor

DRUG CLASS:

Hedgehog cell-signalling pathway inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1	glasdegib Sensitive: A1 - Approval glasdegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2
SMO mutation	Basal Cell Carcinoma	SMO mutation	Basal Cell Carcinoma	vismodegib Resistant: B - Late Trials vismodegib Resistant : B	vismodegib Resistant: B - Late Trials vismodegib Resistant : B
PTCH1 mutation	Medulloblastoma	PTCH1 mutation	Medulloblastoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Melanoma	PTCH1 mutation	Melanoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GLI1 overexpression	Basal Cell Carcinoma	GLI1 overexpression	Basal Cell Carcinoma	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3
PTCH1 mutation	Salivary Gland Cancer	PTCH1 mutation	Salivary Gland Cancer	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GAS1 underexpression	Basal Cell Carcinoma	GAS1 underexpression	Basal Cell Carcinoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH E947T	Soft Tissue Sarcoma	PTCH E947T	Soft Tissue Sarcoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
SMO P641A	Meningioma	SMO P641A	Meningioma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3